(Q40891394)

24 September 2017

Antibiotics for treatment of infections caused by MRSA and elimination of MRSA carriage. What are the choices? (English)

1 reference

24 September 2017

Schmitz FJ

1

1 reference

PubMed ID

18611815

24 September 2017

Jones ME

series ordinal

2

1 reference

24 September 2017

1 June 1997

1 reference

International Journal of Antimicrobial Agents

24 September 2017

1 reference

24 September 2017

9

1 reference

24 September 2017

1

1 reference

24 September 2017

1-19

1 reference

Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The worldwide prevalence of methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant Staphylococcus aureus in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The evolving epidemiology of methicillin-resistant Staphylococcus aureus at a university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant Staphylococcus aureus (MRSA): a briefing for acute care hospitals and nursing facilities. The AHA Technical Panel on Infections Within Hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Antimicrobial-resistant pathogens in the 1990s

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Origin and evolution of DNA associated with resistance to methicillin in staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

New mechanism for methicillin resistance in Staphylococcus aureus: clinical isolates that lack the PBP 2a gene and contain normal penicillin-binding proteins with modified penicillin-binding capacity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Borderline susceptibility to antistaphylococcal penicillins is not conferred exclusively by the hyperproduction of beta-lactamase

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Vancomycin therapy for methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant staphylococci: detection methods and treatment of infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Mode of action and in-vitro activity of vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Treatment of infections due to methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Staphylococcus aureus and vancomycin: the sequel

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Structure, biochemistry and mechanism of action of glycopeptide antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The role of Gram-positive therapy in the neutropenic patient

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Towards the ideal glycopeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The antimicrobial activity of fusidic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Vancomycin in infants and children: a review of pharmacology and indications for therapy and prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

A prospective study of adverse reactions associated with vancomycin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Lipohypertrophy and glomerulonephritis after the use of aprotinin in an insulin-dependent diabetic.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The "red man's syndrome" and slow infusion of vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Influence of antihistamine pretreatment on vancomycin-induced red-man syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Vancomycin Therapy in Patients with Impaired Renal Function: A Nomogram for Dosage

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Persistence of Vancomycin in the Blood during Renal Failure and Its Treatment by Hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Staphylococcal sepsis in patients on chronic hemodialysis regimens: intravenous treatment with vancomycin given once weekly

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Topical vancomycin for the treatment of Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus conjunctivitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Instillation of vancomycin into a cerebrospinal fluid reservoir to clear infection: pharmacokinetic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

A risk-benefit assessment of teicoplanin in the treatment of infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Microbiological properties of teicoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Dosage recommendations for teicoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Clinical evaluation of teicoplanin in the treatment of gram-positive bacterial intravascular infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

A review of the safety profile of teicoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Teicoplanin in endocarditis: a multicentre, open European study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Protection against gentamicin nephrotoxicity by daptomycin in nephrectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro activity of the semisynthetic glycopeptide amide MDL 63,246

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Structure-activity relationships of vancomycin-type glycopeptide antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparative activity of CGP 31608, nafcillin, cefamandole, imipenem, and vancomycin against methicillin-susceptible and methicillin-resistant staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Imipenem therapy of experimental Staphylococcus epidermidis endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Clinical, epidemiologic and bacteriologic observations of an outbreak of methicillin-resistant Staphylococcus aureus at a large community hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Efficacy of prophylaxis with beta-lactams and beta-lactam-beta-lactamase inhibitor combinations against wound infection by methicillin-resistant and borderline-susceptible Staphylococcus aureus in a guinea pig model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Beta-Lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Emergence of resistance to cephalothin and gentamicin during combination therapy for methicillin-resistant Staphylococcus aureus endocarditis in rabbits.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Efficacy of ticarcillin-clavulanic acid for treatment of experimental Staphylococcus aureus endocarditis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Efficacy of ampicillin plus a beta-lactamase inhibitor (CP-45,899) in experimental endocarditis due to Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Excellent activity of FK037, a novel parenteral broad-spectrum cephalosporin, against methicillin-resistant staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Antibacterial properties of SCE-2787, a new cephem antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with a broad antibacterial spectrum

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Discovery and structure-activity relationship of a series of 1-carba-1-dethiacephems exhibiting activity against methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo antibacterial activities of BO-2727, a new carbapenem

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Epidemiological study of Staphylococcus aureus resistance to new quinolones in a university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Molecular epidemiology and antimicrobial susceptibility testing. Testing of quinolone-resistant Staphylococcus aureus strains isolated in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Epidemiology of ciprofloxacin resistance among patients with methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Oxacillin- and quinolone-resistant Staphylococcus aureus in Sao Paulo, Brazil: a multicenter molecular epidemiology study.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital. An in vitro look at alternative antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro activity of various antimicrobial agents against Staphylococcus aureus isolates including fluoroquinolone- and oxacillin-resistant strains

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Oral temafloxacin versus vancomycin for therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Fluoroquinolone resistance an evolving national problem or just a problem for some physicians?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

New quinolones and gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Antimicrobial activity of DV-7751a, a new fluoroquinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Trimethoprim-sulphamethoxazole treatment in staphylococcal endocarditis and gram-negative septicemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo efficacy of the combination trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Trimethoprim-sulfamethoxazole treatment of multiantibiotic-resistant staphylococcal endocarditis and meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In-vitro and in-vivo studies of trimethoprim-sulphamethoxazole against multiple resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Emergence of gentamicin- and methicillin-resistant Staphylococcus aureus strains in New York City hospitals.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Levels of rifampin and ciprofloxacin in nasal secretions: correlation with MIC90 and eradication of nasopharyngeal carriage of bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Clinical Study of Combination Therapy with Oxacillin and Rifampin for Staphylococcal Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The Efficacy of Rifampin as Adjunctive Therapy in Selected Cases of Staphylococcal Endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Efficacy of short courses of oral novobiocin-rifampin in eradicating carrier state of methicillin-resistant Staphylococcus aureus and in vitro killing studies of clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Rifampin resistance. Development during the therapy of methicillin-resistant Staphylococcus aureus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro activity of minocycline and rifampin against staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Antistaphylococcal Activity of Rifampin with Other Antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Clindamycin for colonization and infection by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Activity of clindamycin against Staphylococcus aureus and Staphylococcus epidermidis from four UK centres

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

1 reference

7 January 2021

Letter: Syntheses of 1-n-(S)-4-amino-2-hydroxybutyryl)-kanamycin B and -3', 4'-dideoxykanamycin B active against kanamycin-resistant bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Antimicrobial chemotherapy of septicemia due to methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Adverse reactions to intravenous administration of fusidic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Fucidin for staphylococcal infection of burns

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

A fatal infection caused by methicillin-resistant Staphylococcus aureus acquiring resistance to gentamicin and fusidic acid during therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Failure of a combination of vancomycin and fusidic acid in a patient with staphylococcal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

A multicentre, open, clinical trial of a new intravenous formulation of fusidic acid in severe staphylococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Susceptibility of methicillin-resistant Staphylococcus aureus to minocycline and other antimicrobials.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Minocycline as an alternative antistaphylococcal agent

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Synergistic interaction of antibiotics with nasal penetration to methicillin-sensitive and methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo study of fosfomycin in methicillin-resistant Staphylococcus aureus septicaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Recent developments in the field of phosphonic acid antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

RP 59500: a proposed mechanism for its bactericidal activity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The molecular basis of the inhibitory activities of type A and type B synergimycins and related antibiotics on ribosomes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparative in-vitro activity of RP 59500 against clinical bacterial isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Evolution and present situation of Staphylococcus aureus sensitivity to MLS in hospital (1975-83).

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The carrier state: methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Epidemiologic studies of an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

An Outbreak of Infections Caused by Strains of Staphylococcus aureus Resistant to Methicillin and Aminoglycosides. II. Epidemiologic Studies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant Staphylococcus aureus: microbiologic characteristics, antimicrobial susceptibilities, and assessment of virulence of an epidemic strain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

SOME ASPECTS OF NASAL CARRIAGE OF STAPHYLOCOCCI

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

PERSON-TO-PERSON TRANSMISSION OF STAPHYLOCOCCUS AUREUS. QUANTITATIVE CHARACTERIZATION OF NASAL CARRIERS SPREADING INFECTION

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant Staphylococcus aureus nasal carriage and infections in CAPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant staphylococcal colonization and infection in a long-term care facility.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

A comparison of clinical virulence of nosocomially acquired methicillin-resistant and methicillin-sensitive Staphylococcus aureus infections in a university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The effect of methicillin on skin lesions in guinea-pigs caused by "methicillin-sensitive" and "methicillin-resistant" Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Nasal carriage of Staphylococcus aureus and cross-contamination in a surgical intensive care unit: efficacy of mupirocin ointment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Prospective study of infection, colonization and carriage of methicillin-resistant Staphylococcus aureus in an outbreak affecting 990 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Effectiveness of simple measures to control an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections in an intensive care unit.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Control of epidemic methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The value of nasal mupirocin in containing an outbreak of methicillin-resistant Staphylococcus aureus in an orthopaedic unit

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-Resistant Staphylococcus aureus in Hospitals and Long-Term Care Facilities: Microbiology, Epidemiology, and Preventive Measures

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Mupirocin ('pseudomonic acid')--a promising new topical antimicrobial agent

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Minimal dose requirements for nasal mupirocin and its role in the control of epidemic MRSA.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Eradication of colonization by methicillin-resistant Staphylococcus aureus by using oral minocycline-rifampin and topical mupirocin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

An outbreak of infection with a methicillin-resistant Staphylococcus aureus in a special care baby unit: value of topical mupirocin and of traditional methods of infection control

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Nasal carriage of Staphylococcus aureus treated with topical mupirocin (pseudomonic acid) in a children's hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Elimination of nasal carriage of methicillin-resistant Staphylococcus aureus with mupirocin during a hospital outbreak.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Mupirocin resistance among consecutive isolates of oxacillin-resistant and borderline oxacillin-resistant Staphylococcus aureus at a university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparison of the in-vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Topical antibiotic ointments for staphylococcal nasal carriers: survey of current practices and comparison of bacitracin and vancomycin ointments

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Interaction of pseudomonic acid A with Escherichia coli B isoleucyl-tRNA synthetase

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Biochemical basis of mupirocin resistance in strains of Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Mechanism of mupirocin transport into sensitive and resistant bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Diversity of staphylococci exhibiting high-level resistance to mupirocin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The antimicrobial activity of mupirocin—an update on resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Sensitivity to mupirocin of staphylococci isolated from colonized or infected patients in Germany

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant Staphylococcus aureus in a London hospital.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

10.1016/S0924-8579(97)00027-7

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

18611815